A patient with headache on most days of the month has been told by her neurologist that Botox is the next step, and by her plan’s phone line that it “may require prior authorization.” She wants to know one thing before she books anything: is it covered, or is she about to be handed a bill? The answer is yes for chronic migraine, with a short list of conditions attached, and the conditions are where most of the delays and denials live. This post walks through what the plans require, why claims get denied and how they get fixed, what the treatment costs if a plan will not pay, and how long the whole process takes at Modal Pain Management in Midtown Manhattan.
What “covered” means for Botox: a drug and a procedure
Botox for migraine is two things on a claim. The drug — 155 units of onabotulinumtoxinA — is billed under your medical benefit, either from the physician’s stock or, on some plans, supplied through a specialty pharmacy that ships it to the office. The procedure — 31 injections across seven muscle groups of the head and neck, the fixed PREEMPT map — is billed separately as the injection service. Prior authorization covers both, and a denial on either half stalls the whole thing. That is why “is it covered?” has a two-part answer: the indication has to be right, and the paperwork has to match the plan’s rules for both pieces.
The indication comes from the FDA label and the International Classification of Headache Disorders. Botox is approved for the prevention of headaches in adults with chronic migraine — headache on 15 or more days a month lasting four hours or longer — and ICHD-3 defines chronic migraine as that pattern for more than three months with migraine features on at least 8 days a month (ICHD-3, 2018). The evidence behind the indication is the PREEMPT program, 1,384 adults with exactly that pattern, in whom Botox reduced headache days by 8.4 a month at 24 weeks against 6.6 with placebo, with the difference widening over repeated cycles (Dodick 2010). Botox was also tested in episodic migraine and did not separate from placebo, which is the reason no plan covers it below the 15-day line.
The four things every authorization has to document
The plans differ in wording and in a few thresholds, but the authorization form is built around the same four facts.
Headache days. Fifteen or more a month, for more than three months. The plan wants a headache diary, not an estimate. If you do not keep one, start today — a calendar app with a mark on every headache day is enough — because the three-month clock runs from the first entry.
Migraine days. At least 8 of those days have to carry migraine features: one-sided or throbbing pain, moderate to severe intensity, worse with routine activity, nausea, sensitivity to light and sound, or aura — or respond to a triptan. Daily headache without those features is chronic tension-type headache, cervicogenic headache, or medication-overuse headache, and Botox is neither approved nor covered for it.
Duration. Headaches lasting four hours or longer untreated. Short, stabbing, or minutes-long headaches are a different diagnosis.
Preventive trials. At least two oral preventive classes — beta-blocker, anticonvulsant, antidepressant, on some plans an ARB or a calcium-channel blocker — at an adequate dose for two to three months each, that failed or were not tolerated. Some plans require three. A documented contraindication usually counts in place of a trial. Since the American Headache Society’s 2024 position that CGRP-targeting therapies are first-line preventives (Charles 2024), a growing number of plans count a CGRP antibody or gepant as a qualifying trial, and the 2021 consensus statement already recognized Botox and the CGRP drugs as options that can be used together in chronic migraine (Ailani 2021).
One thing that does not disqualify anyone: medication overuse. Acute medication on 10 or more days a month was present in about two-thirds of the PREEMPT patients, and they responded. It is addressed at the same visit — the taper is planned alongside the injections — but it does not close the door. Whether you meet all four criteria takes two minutes to check with our chronic migraine Botox eligibility check.
Why claims get denied, and how they get fixed
Denials are almost never a disagreement about whether you have chronic migraine. They are documentation problems, and each one has a fix.
The diary is missing or thin. The plan sees “patient reports frequent headaches” and denies for lack of a 15-day count. The fix is a three-month diary, which is also the reason we ask for it before submitting rather than after a denial.
The preventive trials are undocumented, too short, or from one class. Two months of topiramate that was stopped for side effects counts. Two weeks of it does not. Two beta-blockers count as one class. The fix is a medication history with drug, dose, duration, and outcome for each trial, which the consultation builds with you.
The diagnosis code is wrong. A claim coded as episodic migraine, tension-type headache, or unspecified headache is denied on sight. The fix is a diagnosis of chronic migraine supported by the exam and the diary.
The drug came through the wrong channel. Some plans require Botox from their specialty pharmacy, delivered to the office for your session, and deny drug supplied from the physician’s stock. The fix is knowing the plan’s rule before the first session, which the benefits check establishes.
The continuation was not justified. After the first two or three cycles most plans ask for evidence that headache days dropped. The fix is the same diary, kept through treatment. Patients who stop keeping it are the ones whose fourth cycle gets denied.
A peer-to-peer review — Dr. Movshis on the phone with the plan’s medical director — resolves most of what the paperwork does not, usually inside the original 7–14 business-day window.
What it costs if the plan will not pay, or you would rather not wait
Self-pay Botox for chronic migraine at Modal Pain Management is $2,000 per session for the 155-unit PREEMPT protocol, all-inclusive: the physician fee, the 31 injections, and the drug. Sessions are every 12 weeks, so a year of treatment is four sessions. Additional follow-the-pain units, when used, are priced per unit on the self-pay pricing page, which also lists the per-unit prices of Botox, Dysport, and Daxxify for the other indications. Payment plans through Cherry, including 0%-APR options on shorter terms, are available through our financing page. HSA and FSA cards are accepted. For patients with out-of-network benefits we provide a superbill with the CPT and ICD-10 codes so you can submit for reimbursement yourself.
Two things to know about the insured route. First, the manufacturer’s Botox Savings Program reimburses part of the out-of-pocket cost of the drug for eligible patients with commercial insurance, and our office checks eligibility with you. It is not available to patients on government plans. Second, your deductible status matters more than the plan’s coverage decision for what you actually pay in the first cycle. Ask for the benefits check before you schedule, and you will know both numbers before the first injection. What we will not do is quote what any plan allows for the drug or the procedure, because those figures are plan-specific and contractual, and a number quoted from someone else’s plan is worse than no number.
The timeline at Modal Pain Management
The consultation is 45 minutes. Bring your headache diary, your preventive-medication history with doses and durations, and any imaging. Dr. Movshis examines for the headaches that mimic migraine — the one that starts at the base of the skull and never switches sides is usually cervicogenic, and plans will not cover Botox for it, but they do cover the third occipital nerve block that treats it. If chronic migraine is confirmed and the criteria are met, the authorization is submitted the same day. Approval typically takes 7–14 business days, and the first session is generally scheduled within 2–3 weeks of the visit. The session takes about 15 minutes. The 72-second film shows what the injections do at the nerve endings, and the Botox for chronic migraine page covers the protocol, the side effects, and what to expect over the first three cycles.
If you are not sure which side of the 15-day line you are on, keep the diary for a month and take the eligibility check. If you already know, the consultation is the next step, and verifying your insurance before it means the authorization starts the day you are seen.
References
This article is reviewed against the peer-reviewed literature. Citations retrieved from PubMed.
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018. doi:10.1177/0333102417738202 · PubMed
- Dodick DW, Turkel CC, DeGryse RE, et al.. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010. doi:10.1111/j.1526-4610.2010.01678.x · PubMed
- Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021. doi:10.1111/head.14153 · PubMed
- Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024. doi:10.1111/head.14692 · PubMed
Frequently Asked Questions
For chronic migraine, usually yes. Botox (onabotulinumtoxinA) has an FDA indication for the prevention of headaches in adults with chronic migraine, and most commercial PPO plans cover both the drug and the injection procedure with prior authorization. The authorization has to document four things: headache on 15 or more days a month for more than three months, migraine features on at least 8 of those days, headaches lasting four hours or longer, and trials of at least two oral preventive medications that failed or were not tolerated. Botox is not covered for episodic migraine (fewer than 15 headache days a month) or for tension-type or cervicogenic headache, because it is not approved for them and did not work for them in trials. Modal Pain Management submits the authorization for you after the consultation. We do not participate with Medicare or Medicaid.
What you pay depends on your plan's deductible, coinsurance, and whether the drug runs through your medical benefit or a specialty pharmacy, so there is no single number, and we do not quote what individual plans allow. Three things reliably lower the cost for commercially insured patients: prior authorization approved before the first session (so nothing is billed as unauthorized), the manufacturer's Botox Savings Program, which reimburses part of the out-of-pocket cost of the drug for eligible commercially insured patients and which our office checks with you, and knowing your deductible status before you start, since the first cycle of the plan year often lands on it. Our team verifies benefits and tells you what to expect before scheduling.
At Modal Pain Management the self-pay price for the 155-unit PREEMPT protocol is $2,000 per session, all-inclusive — the physician fee, the 31 injections, and the drug — repeated every 12 weeks, so a full year of treatment is four sessions. Additional follow-the-pain units, when used, are priced per unit on our self-pay pricing page. Payment plans through Cherry are available, HSA and FSA cards are accepted, and we provide a superbill with the CPT and ICD-10 codes so patients with out-of-network benefits can submit for reimbursement. Self-pay is the route patients take when their plan will not cover Botox yet — usually because the two preventive trials are not documented — or when they prefer to skip the authorization step.
The common denials are documentation problems, not disagreements about the diagnosis. The headache diary is missing or does not show 15 days a month for three months. The preventive trials are undocumented, too short (most plans want two to three months at an adequate dose), or all from the same class. The diagnosis on the claim is episodic migraine, tension-type headache, or unspecified headache rather than chronic migraine. The drug was ordered through the wrong channel — some plans require it from a specialty pharmacy rather than from the physician's stock. Or a continuation request after the first cycles did not document the reduction in headache days the plan requires. Every one of those is fixable with the right paperwork, which is why our office builds the authorization from your diary and medication history rather than asking you to assemble it.
After the consultation our office submits the prior authorization with your diagnosis, headache diary, and medication history. Approval typically takes 7–14 business days, and the first injection session is generally scheduled within 2–3 weeks of the visit. If the plan requests more information, a peer-to-peer review with Dr. Movshis usually resolves it within the same window. Continuation authorizations after the first two or three cycles are submitted with your updated diary and are typically faster.
Almost always, yes: at least two oral preventive classes — a beta-blocker such as propranolol or metoprolol, an anticonvulsant such as topiramate or divalproex, an antidepressant such as amitriptyline, nortriptyline, or venlafaxine — each at an adequate dose for two to three months, that either did not work or could not be tolerated. Some plans require three. A documented contraindication to a class usually counts in place of a trial, and a growing number of plans count a CGRP-targeting preventive (erenumab, fremanezumab, galcanezumab, eptinezumab, atogepant, or rimegepant) as a qualifying trial, following the American Headache Society's 2024 position that those drugs are first-line. If your trials are incomplete, the consultation starts and documents them so the authorization can follow.
